Drug Toxicity Leads to Early Discontinuation of Niraparib in Ovarian Cancer Treatment

Drug Toxicity and Early Discontinuation of Niraparib in Ovarian Cancer

Drug toxicity has been identified as the most common reason for the early discontinuation of first-line maintenance monotherapy with niraparib (Zejula) among patients with epithelial ovarian cancer, according to findings from the real-world CHAR1ZMA study. This research, published in the International Journal of Gynecological Cancer, emphasizes the critical need for healthcare providers to focus on effective toxicity management, particularly during the initial 90 days of treatment, and to consider individualized starting doses based on patient-specific factors.

Study Overview

The CHAR1ZMA study analyzed electronic health records of 560 adult patients with epithelial ovarian cancer who received niraparib as a first-line monotherapy. The study period spanned from January 2017 to December 2022, with patients diagnosed no earlier than January 2015. Among the participants, 161 discontinued treatment early, while 399 did not.

Key Findings

• Toxicity as a Primary Cause: 67.7% of early discontinuers cited toxicity as the reason, compared to 18.1% in those who did not discontinue early.
• Dose Modifications: Early discontinuers were less likely to undergo dose modifications (29.8% vs. 53.6% in non-early discontinuers).
• Disease Progression: In contrast, disease progression was the most common reason for discontinuation among non-early discontinuers (74.8% vs. 30.4% in early discontinuers).
• Treatment Duration: The median treatment duration was 7.2 months overall, with a significant difference between early discontinuers and those who continued treatment (4.5 months longer in the latter group).

Importance of Individualized Starting Doses

The study also highlighted the role of individualized starting doses (ISDs) based on body weight and platelet count. A majority of patients (58.8%) received niraparib at their ISD, with variations in dosage affecting treatment outcomes. Early discontinuers were more likely to receive doses higher than their ISD, suggesting a missed opportunity for appropriate dose modifications.

Conclusion

Researchers advocate for enhanced education among healthcare providers on the importance of early clinical management of toxicity, including the use of ISDs and timely dose modifications. Such strategies could enable patients to remain on first-line maintenance niraparib treatment longer, thereby experiencing the full therapeutic benefits.

Reference: Backes FJ, Boyle TAC, Lim J, et al. Real-world duration of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer in the United States: the CHAR1ZMA study. Int J Gynecol Cancer. 2024;0(0):1-9. doi: doi.org/10.1016/j.ijgc.2024.100044